EL7.AI
StocksMedium•16 November 2026•
4 min read

Kyntra Bio reports $0.2 million in net income in the third quarter

Key Facts

1Net income from continuing operations was $0.2 million in the third quarter of 2026, compared with a loss of $13.1 million a year earlier.
2Revenue from continuing operations rose to $1.8 million, from $1.1 million in the third quarter of 2025.
3Cash, investments and accounts receivable totaled $44.1 million as of September 30, 2026, and the company expects to fund operations through 2028.
4The company expects discontinuing the study to save more than $20 million in operating expenses in 2027 and 2028.

Kyntra Bio announced on November 16, 2026, that it recorded net income from continuing operations of $0.2 million in the third quarter, compared with a net loss of $13.1 million in the same period a year earlier. Net income was $0.04 per basic and diluted share, according to the company. The announcement came after the market close, while KYNB shares had ended the November 13 session at $3.44, down from $3.59 in the previous session. The reported share-price move therefore preceded publication of the results and does not represent a response to them. The results center on a turnaround in net income, alongside financing and operational changes announced by the company.

Revenue from continuing operations rose to $1.8 million in the third quarter of 2026, compared with $1.1 million in the corresponding quarter of 2025, according to the company. The company thus recorded higher revenue alongside a shift to positive net income from continuing operations. The comparison between the two periods relates to the reported results for continuing operations, in both revenue and net income. The disclosure provided here did not include analyst estimates, so the comparison is limited to the same period a year earlier. The company also presented financing and liquidity changes in the context of its operational shift.

On financing, Kyntra Bio said an amendment to its royalty financing agreement reduced the maximum aggregate payments from $125 million to $65 million. The amendment included an accelerated upfront payment of $42.6 million, with a cap of $15 million on the remaining royalty-linked payments. The company said in August that the amendment reduced its future obligations under the agreement by $60 million. At the time, it also estimated that its cash runway would extend through the fourth quarter of 2027 after the upfront payment. In its third-quarter results disclosure, cash, cash equivalents, investments and accounts receivable totaled $44.1 million as of September 30, 2026, and the company said it expects those resources to fund operating plans through 2028.

The company announced it would discontinue development of FG-3246 and FG-3180 after initial efficacy results in the prespecified interim analysis failed to meet the threshold for continued development. Regarding FG-3246, it said it had decided to close enrollment in the Phase 2 trial and end development of the program after the interim analysis showed insufficient efficacy. Chief Executive Officer Thane Wittig said the decision was made "after a prespecified interim analysis showed insufficient efficacy," adding that the company continues to work toward completing its transition to a rare-disease-focused company. Kyntra Bio expects ending the study to save more than $20 million in operating expenses in 2027 and 2028. The decision reshapes the company's development and spending priorities as it focuses on its roxadustat program.

Kyntra Bio plans to start a pivotal Phase 3 trial of roxadustat in the first quarter of 2027 to treat anemia in patients with lower-risk myelodysplastic syndromes and a high transfusion burden. The company tied the trial's start to securing a strategic partnership or raising external funding, making the announced timing conditional on obtaining one of those options. That puts funding for the next trial among the decisions that will determine the program's course after the two studies are discontinued. The company had scheduled its third-quarter results conference call for November 16, 2026, at 5:00 p.m. Eastern time. In the background to the stock's trading, Nasdaq said in October that the company had not demonstrated compliance with listing requirements by the September 29 deadline, while the company requested a hearing to appeal the delisting decision; the request keeps the shares trading until the panel's decision, and the potential extension period may reach 180 days under the cited rule.

Open on chart